Procter & Gamble Hygiene and Health Care Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
PGHH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Procter & Gamble Hygiene and Health Care has filed audited financial results for the nine-month period ended March 31, 2025, as the company shifted its financial year-end from June 30 to March 31 to align with the common fiscal calendar. Revenue from operations for the nine months stood at Rs. 3,374 crore, with profit after tax of Rs. 636.6 crore and basic EPS of Rs. 196.11. For the standalone fourth quarter (Jan–Mar 2025), revenue was Rs. 991.6 crore and PAT was Rs. 156.1 crore. The Board recommended a final dividend of Rs. 65 per share (on face value of Rs. 10), aggregating to about Rs. 211 crore, to be paid between August 27 and September 23, 2025 subject to shareholder approval. Statutory auditors Kalyaniwalla & Mistry LLP issued an unmodified opinion, and M/s. M K Saraf & Associates LLP was appointed as Secretarial Auditor for five years from FY 2025-26 to FY 2029-30. Operating cash flow remained healthy at Rs. 593 crore, though the company also reversed an earlier impairment of Rs. 6.7 crore after entering an agreement to sell the related plant and equipment.
Shareholders get a healthy final dividend of Rs. 65 per share, and the clean audit opinion with strong cash generation reinforces the company's stable financial profile. The nine-month reporting period makes year-on-year comparison unusual, so investors should focus on the underlying Q4 performance and dividend yield rather than headline growth numbers.